Latest action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Establishes safety standards for human cell and tissue products used in medical treatments.
The problem
Human cell and tissue products lack consistent federal safety regulations, creating risks for patients receiving treatments using these materials.
The proposal
The bill creates federal safety standards and oversight requirements for human cell and tissue products to ensure they meet quality and safety benchmarks.
The impact
Patients, medical facilities, and companies producing cell and tissue products will face new regulatory requirements and standards for these treatments.
Consistent safety standards help prevent contamination and infections. Patients receive treatments with known quality requirements. This reduces serious medical complications from unsafe products.
Businesses know what standards they must meet. Consistent rules across states reduce confusion. Companies can plan and invest with certainty.
Federal oversight increases confidence in these medical treatments. Patients are more likely to use beneficial therapies. Healthcare providers can recommend treatments with confidence.
Federal standards stop low-quality products from entering the market. Inspections and testing catch problems early. Public health is protected.
Meeting new safety standards requires testing and certification. Compliance costs money. These costs may increase prices for patients and healthcare providers.
New regulations may delay approval of new treatments. Patients may wait longer for innovative therapies. Benefits of new products reach people more slowly.
Large companies can afford compliance costs easier than small ones. Small producers may struggle with regulations. Market consolidation could reduce competition.
States may already have their own standards. Federal rules could conflict with state rules. Confusion and overlap may occur without careful coordination.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.